Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting

NEXT STORY
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
PREV STORY
American College of Rheumatology Targets Step Therapy and Drug Pricing in New Position Statements
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

author_avatar
NASDAQ Market News

Retrophin Reports Third Quarter 2018 Financial Results

Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 ...

author_avatar
NASDAQ Market News

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

author_avatar
NASDAQ Market News